Hogan Lovells represented LabCorp, a leading health care diagnostics company, in the acquisition of Chiltern, a specialty contract research organization (CRO) focusing on clinical research services for the pharmaceutical and medical device industries. /p>

The all-cash transaction is expected to close in the fourth quarter of 2017, subject to regulatory approvals and customary closing conditions. Once the transaction is complete, Chiltern will become part of LabCorp’s Covance segment.

Corporate partners Michael Silver and Allen Hicks led the transaction team, which also included Rob Church, Gabi Witt, Natalie Kone and Philip Corser. Other key members of the Hogan Lovells team included Leigh Oliver, Lauren Battaglia, and Alice Wallace-Wright on antitrust matters; Scott McClure, on tax matters; and Michael Applebaum on executive compensation.

Hogan Lovells has advised LabCorp for more than a decade on many of its most significant strategic acquisitions including: Covance, Genzyme Genetics, Pathology Associates Medical Laboratories (PAML), Mount Sinai Health System Clinical Outreach Laboratories, Monogram Biosciences, Medtox, Liposcience and Sequenom.